Eton Pharmaceuticals vs Rockwell Medical
ETON and RMTI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ETON and RMTI compare
Eton Pharmaceuticals is the larger company, worth 68 times as much as Rockwell Medical ($1.8B against $26.6M).
Eton Pharmaceuticals grew revenue faster over the last twelve months (81.5% versus −21.1% for Rockwell Medical).
Eton Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 12.0% compared with −7.3% at Rockwell Medical.
Rockwell Medical scores higher on the StockData Score (11 against 10 for Eton Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ETON | RMTI |
|---|---|---|
| Size and price | ||
| Market cap | $1.8B | $26.6M |
| Share price | $63.65 | $6.61 |
| Change, 1 year | 276% | −28.1% |
| Change, 5 years | 1408% | −86.3% |
| Beta (5Y) | −0.44 | 0.01 |
| Employees | 44 | 157 |
| StockData Score | ||
| Total score | 10 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 4 (better) | 3 |
| Health score | 3 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 163× | – |
| P/S | 17.2× | 0.4× (better) |
| P/B | 39.1× | 0.8× (better) |
| EV/EBITDA | 87.3× | – |
| P/FCF | 123× | 17.3× (better) |
| FCF yield | 0.81% | 5.8% (better) |
| Fair value | $10.20 | $32.27 |
| Margin of safety | −524% | 79.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 81.5% (better) | −21.1% |
| Revenue growth, 5Y average | 360% (better) | 2.2% |
| Profitability | ||
| Gross margin | 57.9% (better) | 17.7% |
| Operating margin | 15.4% (better) | −6.5% |
| Net margin | 12.0% (better) | −7.3% |
| FCF margin | 14.0% (better) | 2.2% |
| Return on equity | 36.0% (better) | −15.5% |
| Return on invested capital | 42.5% (better) | −17.9% |
| Financial health | ||
| Debt / equity | 0.60 | 0.26 (better) |
| Net debt / EBITDA | 0.05 | – |
| Interest coverage | 3.6× (better) | −4.0× |
| Current ratio | 1.52 | 3.25 (better) |
| Altman Z-score | 16.19 (better) | −7.81 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 74.0% | 0.05% |
| Held by insiders | 5.6% | 100% |
| Insider net buying, 12 months | −$35.0M | −$11.6K (better) |
| Short interest, % of float | 7.4% | – |
Go deeper
- ETON stock overview
- ETON income statement
- ETON valuation and score
- RMTI stock overview
- RMTI income statement
- RMTI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.